Venus Remedies Secures New Drug Approvals in Vietnam, Strengthens ASEAN Presence
Mumbai: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), one of the world’s top 10 fixed-dosage injectable manufacturers, has received new marketing authorizations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam. The approvals mark a significant milestone in the company’s expansion across Southeast Asia, raising its total active product approvals in Vietnam to 29.
With over 374 marketing authorizations across ASEAN markets, Venus Remedies continues to reinforce India’s position as a trusted supplier of advanced pharmaceuticals. The latest regulatory clearances further strengthen the company’s footprint in South Asia’s fast-growing healthcare sector, particularly in critical care injectables.
“Southeast Asia remains a strategic geography for Venus, and we are committed to deepening our presence through sustained portfolio diversification and long-term partnerships,” said Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre.
Vietnam ranks among India’s top four pharmaceutical export destinations in Southeast Asia and is its 15th largest trading partner. Bilateral trade in pharmaceuticals has seen consistent growth over the past five years, driven by rising demand for complex generics and affordable oncology and antimicrobial therapies.
“With these approvals, we are deepening our commitment to healthcare providers and patients in Vietnam,” said Aditi K. Chaudhary, President, International Business, Venus Remedies Limited. “Each regulatory milestone helps us build resilient supply chains and forge meaningful collaborations that elevate care standards across borders.”
The ASEAN pharmaceutical market is projected to reach USD 63.5 billion by 2029, underscoring the region’s importance in India’s global trade strategy. Venus Remedies’ expanding regulatory footprint reflects its focus on sustainable growth, regulatory excellence, and equitable access to critical medicines across emerging markets.
